Human Serum Albumin and Dermal BoNT: A Safety Consideration

Background: HSA is widely used as a stabilizer in BoNT formulations and is well tolerated for labeled IM uses. The adoption of intradermal (“dermatoxin,” micro-BoNT) techniques raises a safety question: does placing an HSA-containing injectate directly into the immune-dense dermis elevate the risk of cutaneous hypersensitivity? Innovation/Idea: The authors propose reframing excipient choice as a route-specific safety variable and call for the development and clinical study of HSA-free BoNT formulations (TYEMVERS, JKD Bio, Seoul, Korea) for intradermal applications. Rationale: The dermis contains mast cells, Langerhans cells, dendritic cells, tissue-resident T cells, and robust lymphatic access, promoting rapid antigen sampling. Published reports document HSA-related hypersensitivity ranging from localized reactions to rare anaphylaxis. Given heightened cutaneous immune surveillance, ID administration may increase the likelihood or visibility of excipient-triggered reactions. Implications: A pragmatic evaluation pathway—comparative safety trials, mechanistic substudies, and improved pharmacovigilance—can test this hypothesis. Meanwhile, risk-aware clinical practice (patient selection, counseling, and monitoring) may reduce adverse events while preserving aesthetic outcomes.